Re: Axillary Staging Using Positron Emission Tomography in Breast Cancer Patients Qualifying for Sentinel Lymph Node Biopsy

Breast Journal

Volumn 10, Issue 2, 2004, Pages 83-84

  Bland, Kirby I ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

AXILLARY LYMPH NODE; BREAST CANCER; CANCER INVASION; CANCER PATIENT; CANCER STAGING; EDITORIAL; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; SCINTIGRAPHY; SENTINEL LYMPH NODE BIOPSY; TISSUE SECTION; TUMOR LOCALIZATION;

BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; SENTINEL LYMPH NODE BIOPSY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 1642391782     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1075-122X.2004.10201.x     Document Type: Editorial

References (3)

1. Bobardieri E, Crippa F, Maffioli L, et al. Axillary lymph node metastases detection with nuclear medicine approaches in patients with newly diagnosed breast cancer: Can positron emission tomography (PET) with 18F-FDG be considered as the best method? Int J Oncol 1996;8:693-99.
2. Crippa F, Agresti R, Seregni E, et al. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med 1998;1:4-8.
3. Greco M, Crippa F, Agresti R, et al. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst 2001;8:630-35.